NYSE: NVSNovartis Ag Stock Forecast, Predictions & Price Target
Analyst price target for NVS
Based on 3 analysts offering 12 month price targets for Novartis Ag.
Min Forecast
$104.00+23.60%
Avg Forecast
$106.33+26.38%
Max Forecast
$110.00+30.73%
Should I buy or sell NVS stock?
Strong Buy
Strong Buy
7 analysts 77.78%
Buy
0 analysts 0.00%
Hold
1 analysts 11.11%
Sell
0 analysts 0.00%
Strong Sell
1 analysts 11.11%
Forecast return on equity
Is NVS forecast to generate an efficient return?
Company
30.50%
Industry
55.90%
Market
-1.38%
NVS's Return on Equity is forecast to be high in 4 years (30.50%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast
Forecast return on assets
Is NVS forecast to generate an efficient return on assets?
Company
14.29%
Industry
15.12%
Market
11.51%
NVS is forecast to generate lower Return on Assets (14.29%) than the US Drug Manufacturers - General industry average (15.11%)
Forecast
NVS earnings per share forecast
What is NVS's earnings per share in the next 3 years based on estimates from 5 analysts?
Avg 1 year Forecast
$5.73+11.91%
Avg 2 year Forecast
$6.34+23.79%
Avg 3 year Forecast
$6.78+32.42%
NVS's earnings are forecast to grow at a rate of 10.11% per year, which is not exceptional
Forecast
NVS revenue forecast
What is NVS's revenue in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$49.8B+2.37%
Avg 2 year Forecast
$53.2B+9.26%
Avg 3 year Forecast
$55.5B+13.95%
NVS's revenue is forecast to grow at a rate of 4.56% per year, which is not exceptional
Forecast
NVS earnings growth forecast
How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
10.11%
Industry
19.99%
Market
14.64%
NVS's earnings are forecast to grow slower (10.11% per year) than the US Drug Manufacturers - General industry average (20.03%)
Forecast
NVS's earnings are forecast to grow slower (10.11% per year) than the US market average (14.71%)
Forecast
NVS revenue growth forecast
How is NVS forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
4.56%
Industry
6.41%
Market
5.53%
NVS's revenues are forecast to grow slower (4.56% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
NVS's revenues are forecast to grow slower (4.56% per year) than the US market average (5.62%)
Forecast
Novartis Ag Stock Forecast FAQ
Is Novartis Ag Stock a good buy in 2019, according to Wall Street analysts?
The consensus among 9 Wall Street analysts covering (NYSE: NVS) stock is to Strong Buy NVS stock.
Out of 9 analysts, 7 (77.78%) are recommending NVS as a Strong Buy, 0 (0.00%) are recommending NVS as a Buy, 1 (11.11%) are recommending NVS as a Hold, 0 (0.00%) are recommending NVS as a Sell, and 1 (11.11%) are recommending NVS as a Strong Sell.
What is NVS's Price Target?
According to 3 Wall Street analysts that have issued a 1 year NVS price target, the average NVS price target is $106.33, with the highest NVS stock price forecast at $110.00 and the lowest NVS stock price forecast at $104.00.
On average, Wall Street analysts predict that Novartis Ag's share price could reach $106.33 by Oct 8, 2021. The average Novartis Ag stock price prediction forecasts a potential upside of 24.09% from the current NVS share price of $85.69.
What is NVS's earnings growth forecast for 2020-2022?
(NYSE: NVS) Novartis Ag's forecast annual earnings growth rate of 10.11% is not forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 20.03%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 14.71%.
Novartis Ag's earnings in 2019 is $11,732,000,000.On average, 5 Wall Street analysts forecast NVS's earnings for 2020 to be $13,243,012,288, with the lowest NVS earnings forecast at $13,058,118,574, and the highest NVS earnings forecast at $13,335,459,145. On average, 5 Wall Street analysts forecast NVS's earnings for 2021 to be $14,648,204,517, with the lowest NVS earnings forecast at $14,259,927,717, and the highest NVS earnings forecast at $14,930,167,431.
In 2022, NVS is forecast to generate $15,669,742,289 in earnings, with the lowest earnings forecast at $15,184,396,289 and the highest earnings forecast at $16,155,088,289.
What is NVS's revenue growth forecast for 2020-2022?
(NYSE: NVS) Novartis Ag's forecast annual revenue growth rate of 4.56% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 5.62%.
Novartis Ag's revenue in 2019 is $48,677,000,000.On average, 2 Wall Street analysts forecast NVS's revenue for 2020 to be $115,165,221,628,641, with the lowest NVS revenue forecast at $113,579,307,349,919, and the highest NVS revenue forecast at $116,751,135,907,364. On average, 2 Wall Street analysts forecast NVS's revenue for 2021 to be $122,915,827,462,650, with the lowest NVS revenue forecast at $120,952,129,102,143, and the highest NVS revenue forecast at $124,879,525,823,157.
In 2022, NVS is forecast to generate $128,198,252,436,630 in revenue, with the lowest revenue forecast at $124,946,318,677,455 and the highest revenue forecast at $131,450,186,195,804.
What is NVS's Earnings Per Share (EPS) forecast for 2020-2022?
(NYSE: NVS) Novartis Ag's current Earnings Per Share (EPS) is $5.12. On average, analysts forecast that NVS's EPS will be $5.73 for 2020, with the lowest EPS forecast at $5.65, and the highest EPS forecast at $5.77. On average, analysts forecast that NVS's EPS will be $6.34 for 2021, with the lowest EPS forecast at $6.17, and the highest EPS forecast at $6.46. In 2022, NVS's EPS is forecast to hit $6.78 (min: $6.57, max: $6.99).
What is NVS's forecast return on equity (ROE) for 2020-2023?
(NYSE: NVS) forecast ROE is 30.50%, which is considered strong.
What is NVS's forecast return on assets (ROA) for 2020-2023?
(NYSE: NVS) forecast ROA is 14.29%, which is lower than the forecast US Drug Manufacturers - General industry average of 15.11%.
©2020 WallStreetZen
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
